Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.

Merten OW, Charrier S, Laroudie N, Fauchille S, Dugué C, Jenny C, Audit M, Zanta-Boussif MA, Chautard H, Radrizzani M, Vallanti G, Naldini L, Noguiez-Hellin P, Galy A.

Hum Gene Ther. 2011 Mar;22(3):343-56. doi: 10.1089/hum.2010.060. Epub 2011 Mar 7.

PMID:
21043787
2.

Production of lentiviral vectors for transducing cells from the central nervous system.

Li M, Husic N, Lin Y, Snider BJ.

J Vis Exp. 2012 May 24;(63):e4031. doi: 10.3791/4031.

3.

Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells.

Humbert O, Gisch DW, Wohlfahrt ME, Adams AB, Greenberg PD, Schmitt TM, Trobridge GD, Kiem HP.

Mol Ther. 2016 Aug;24(7):1237-46. doi: 10.1038/mt.2016.70. Epub 2016 Apr 8.

4.

Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.

Mendenhall A, Lesnik J, Mukherjee C, Antes T, Sengupta R.

J Vis Exp. 2012 Apr 8;(62):e3171. doi: 10.3791/3171.

5.

A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease.

Stewart HJ, Fong-Wong L, Strickland I, Chipchase D, Kelleher M, Stevenson L, Thoree V, McCarthy J, Ralph GS, Mitrophanous KA, Radcliffe PA.

Hum Gene Ther. 2011 Mar;22(3):357-69. doi: 10.1089/hum.2010.142. Epub 2011 Feb 10.

PMID:
21070114
6.

Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.

Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, Dropulic B.

J Gene Med. 2005 Jun;7(6):818-34. Erratum in: J Gene Med. 2005 Jun;7(6):835.

PMID:
15693055
7.

RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S, Salvatori F, Mavilio F, Bordignon C, Rizzardi GP, Bovolenta C.

Hum Gene Ther Methods. 2013 Aug;24(4):228-40. doi: 10.1089/hgtb.2012.190. Epub 2013 Aug 3.

8.

B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.

Castiello MC, Scaramuzza S, Pala F, Ferrua F, Uva P, Brigida I, Sereni L, van der Burg M, Ottaviano G, Albert MH, Grazia Roncarolo M, Naldini L, Aiuti A, Villa A, Bosticardo M.

J Allergy Clin Immunol. 2015 Sep;136(3):692-702.e2. doi: 10.1016/j.jaci.2015.01.035. Epub 2015 Mar 16.

9.

Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Zhang XY, Kutner RH, Bialkowska A, Marino MP, Klimstra WB, Reiser J.

Retrovirology. 2010 Jan 25;7:3. doi: 10.1186/1742-4690-7-3.

10.

Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

Kim YS, Wielgosz MM, Hargrove P, Kepes S, Gray J, Persons DA, Nienhuis AW.

Mol Ther. 2010 Jul;18(7):1310-7. doi: 10.1038/mt.2010.48. Epub 2010 Apr 6.

11.

Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.

Dupré L, Trifari S, Follenzi A, Marangoni F, Lain de Lera T, Bernad A, Martino S, Tsuchiya S, Bordignon C, Naldini L, Aiuti A, Roncarolo MG.

Mol Ther. 2004 Nov;10(5):903-15.

12.

Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.

Charrier S, Dupré L, Scaramuzza S, Jeanson-Leh L, Blundell MP, Danos O, Cattaneo F, Aiuti A, Eckenberg R, Thrasher AJ, Roncarolo MG, Galy A.

Gene Ther. 2007 Mar;14(5):415-28. Epub 2006 Oct 19.

PMID:
17051251
13.

Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64.

Kumar M, Bradow BP, Zimmerberg J.

Hum Gene Ther. 2003 Jan 1;14(1):67-77.

PMID:
12573060
14.

Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.

Carbonaro Sarracino D, Tarantal AF, Lee CC, Martinez M, Jin X, Wang X, Hardee CL, Geiger S, Kahl CA, Kohn DB.

Mol Ther. 2014 Oct;22(10):1803-16. doi: 10.1038/mt.2014.88. Epub 2014 Jun 13.

15.

Efficient large volume lentiviral vector production using flow electroporation.

Witting SR, Li LH, Jasti A, Allen C, Cornetta K, Brady J, Shivakumar R, Peshwa MV.

Hum Gene Ther. 2012 Feb;23(2):243-9. doi: 10.1089/hum.2011.088. Epub 2011 Oct 24.

16.

Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures.

Ansorge S, Lanthier S, Transfiguracion J, Durocher Y, Henry O, Kamen A.

J Gene Med. 2009 Oct;11(10):868-76. doi: 10.1002/jgm.1370.

PMID:
19618482
17.

Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.

Toscano MG, Frecha C, Benabdellah K, Cobo M, Blundell M, Thrasher AJ, García-Olivares E, Molina IJ, Martin F.

Hum Gene Ther. 2008 Feb;19(2):179-97. doi: 10.1089/hum.2007.098.

PMID:
18240968
18.

Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein.

Di Nunzio F, Piovani B, Cosset FL, Mavilio F, Stornaiuolo A.

Hum Gene Ther. 2007 Sep;18(9):811-20.

PMID:
17824830
19.
20.

Integrated strategy for the production of therapeutic retroviral vectors.

Carrondo M, Panet A, Wirth D, Coroadinha AS, Cruz P, Falk H, Schucht R, Dupont F, Geny-Fiamma C, Merten OW, Hauser H.

Hum Gene Ther. 2011 Mar;22(3):370-9. doi: 10.1089/hum.2009.165. Epub 2011 Mar 2.

PMID:
21043806

Supplemental Content

Support Center